Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer

  • Mutlu H
  • Büyükçelik A
  • Akça Z
 et al. 
  • 7


    Mendeley users who have this article in their library.
  • 0


    Citations of this article.


Capecitabine plus lapatinib combination is an effective chemotherapy regimen in patients with advanced breast cancer. Neurological adverse effects secondary to this regimen were reported rarely in literature. A woman with breast cancer presented with complaints of slurred speech while using the capecitabine and lapatinib combination. Her major complaint was slurred speech. No other radiologic or laboratory disorders were detected in the patient. Slurred speech improved one week after the capecitabine and lapatinib combination was discontinued without any further intervention.

Author-supplied keywords

  • Capecitabine
  • adverse event
  • breast cancer
  • lapatinib
  • speech

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Hasan Mutlu

  • Abdullah Büyükçelik

  • Zeki Akça

  • Abdülsamet Erden

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free